Bioenergetics failure in neurodegenerative diseases: Back to the future

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 4, 2012, Pages 351-354

  Saxena, Uday ^a  

^a Kareus Therapeutics   (Switzerland)

Author keywords

bioenergetics; cognition; disease modifying drugs; hypometabolism; motor function; neurons

Indexed keywords

ALZHEIMER DISEASE; BIOENERGY; BRAIN NERVE CELL; DEGENERATIVE DISEASE; ENERGY CONSUMPTION; ENERGY METABOLISM; HUMAN; HUNTINGTON CHOREA; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW;

ENERGY METABOLISM; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84859612938     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.664135     Document Type: Review

References (17)

1. Saxena U. Alzheimer's disease amyloid hypothesis at cross roads: where do we go from here? Expert Opin Ther Targets 2010;14:1273-7
2. Saxena U. Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol 2011;3:133-9
3. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008;1147:180-95 A good overview of bioenergetics failure in Alzheimer's disease.
4. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36:811-22
5. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510 (Pubitemid 40591181)
6. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23:185-98
7. Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients J Nucl Med. 2011;52:173-9
8. Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet 2010;19(R1):R21-7 A good review of molecular defects in disease genesis.
9. Zheng B, Liao Z, Locascio JJ, et al. Global PD Gene Expression (GPEX) consortium. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52-73
10. Ebrahim AS, Ko LW, Yen SH. Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci Lett 2010;473:120-5
11. Pappata S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77:1357-62
12. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52:848-55
13. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010;90:905-81 A good review of the disease process and potential targets for drug discovery.
14. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010;1802:52-61
15. Kuwert T, Lange HW, Boecker H, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J Neurol 1993;241:31-6 (Pubitemid 23342424)
16. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-7
17. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993;43:2689-95 (Pubitemid 24004570)